Shand Lynne, Lunt Mark, Nihtyanova Svetlana, Hoseini Mansour, Silman Alan, Black Carol M, Denton Christopher P
Royal Free Hospital, London, UK.
Arthritis Rheum. 2007 Jul;56(7):2422-31. doi: 10.1002/art.22721.
To explore the relationship between changes in the severity of skin disease and morbidity and mortality in patients with diffuse cutaneous systemic sclerosis (dcSSc).
From a large single-center cohort, we identified 225 patients with dcSSc for whom serial clinical information was available from within 24 months of the onset of the first non-Raynaud's phenomenon manifestation of SSc. The end points analyzed included death and heart, lung, kidney, and gastrointestinal tract involvement. Latent linear trajectory modeling (LTM) was applied to identify patients with a similar trajectory of modified Rodnan skin thickness score (MRSS) changes over the first 3 years of followup. Clinical outcomes were compared between 3 different LTM subgroups.
LTM permitted classification of 131 patients (58%) into 1 of 3 subgroups with different skin score trajectories. Survival was lowest in the subgroup of patients who had a high baseline skin score and experienced little improvement during followup (P = 0.003). However, the frequency of clinical end points was similar in the subgroup with the most favorable trajectory (i.e., a low initial MRSS and subsequent improvement) and the subgroup with a high baseline MRSS and no improvement. Interestingly, the end point frequency was greatest in the subgroup with a high initial MRSS and subsequent improvement, suggesting that sustained severe skin disease does not necessarily predict the number of visceral complications, and that the relationship between the skin score and internal organ involvement in dcSSc is more complex than previously thought.
Although mortality was highest among patients with the worst skin-related outcomes, no simple relationship between burden of disease and change in skin score was observed.
探讨弥漫性皮肤系统性硬化症(dcSSc)患者皮肤疾病严重程度变化与发病率及死亡率之间的关系。
从一个大型单中心队列中,我们确定了225例dcSSc患者,这些患者在系统性硬化症首次非雷诺现象表现出现后的24个月内有系列临床信息。分析的终点包括死亡以及心脏、肺、肾脏和胃肠道受累情况。应用潜在线性轨迹模型(LTM)来识别在随访的前3年中改良罗德南皮肤厚度评分(MRSS)变化轨迹相似的患者。比较了3个不同LTM亚组之间的临床结局。
LTM可将131例患者(58%)分为3个具有不同皮肤评分轨迹的亚组之一。基线皮肤评分高且随访期间改善甚微的亚组患者生存率最低(P = 0.003)。然而,轨迹最有利的亚组(即初始MRSS低且随后有所改善)和基线MRSS高且无改善的亚组临床终点频率相似。有趣的是,初始MRSS高且随后有所改善的亚组终点频率最高,这表明持续的严重皮肤疾病不一定能预测内脏并发症的数量,并且dcSSc中皮肤评分与内脏器官受累之间的关系比之前认为的更为复杂。
尽管皮肤相关结局最差的患者死亡率最高,但未观察到疾病负担与皮肤评分变化之间存在简单的关系。